GenPAx

GenPAx is a biotechnology company focused on pathogen genomics, specifically addressing the global challenge of antimicrobial resistance (AMR) through whole genome sequencing (WGS).

Reviewed by 7wData
Share Email

On this page

Profile

GenPAx provides a platform for tracking bacterial pathogens and their antibiotic resistance using whole genome sequencing.

GenPAx is a biotechnology company focused on pathogen genomics, specifically addressing the global challenge of antimicrobial resistance (AMR) through whole genome sequencing (WGS). Founded by a multidisciplinary team of experts, the company aims to revolutionize bacterial pathogen tracking and AMR surveillance. Its flagship platform, IDEM, provides high-resolution, automated WGS analysis designed to integrate healthcare systems, governments, and industries into a unified global surveillance ecosystem.

GenPAx targets a critical public health issue, with projections suggesting 10 million annual deaths from AMR by 2050. The company operates at the intersection of healthcare, public health, and One Health initiatives, offering solutions that promise unprecedented accuracy in strain identification and data comparability across multiple sites. While financials and headcount are not publicly disclosed, GenPAx's focus on scalable, connectable WGS analysis positions it as a potential leader in a niche but rapidly growing market. Recent appearances at industry conferences like ASM Microbe 2024 suggest active engagement with the scientific community.

Track GenPAx and 240+ vendors.

335k+ subscribers read the daily AI & data note. One email, both newsletters. Unsubscribe anytime.

Who buys this

  • Healthcare institutions needing infection prevention tools
  • Public health agencies monitoring disease outbreaks
  • Food safety and agriculture sectors under One Health initiatives
  • Pharmaceutical and biotech R&D teams

Strengths and what to watch

Strengths

  • Specialized focus on AMR, a high-priority global health challenge
  • IDEM platform's claimed ability to deliver high-resolution, comparable genomic data across sites
  • Multidisciplinary team with expertise spanning genomics, public health, and data integration

Watch for

  • Limited public financial disclosures raise questions about commercial traction
  • Dependence on widespread WGS adoption in healthcare systems still in early stages
  • Potential competition from established diagnostic companies expanding into genomic surveillance

Key Information

Founded
2020
Headquarters
Bern

Frequently Asked Questions

What is GenPAx?

GenPAx is a biotechnology company specializing in pathogen genomics, focusing on antimicrobial resistance (AMR) through whole genome sequencing. Its IDEM platform automates high-resolution genomic analysis, aiming to create a global surveillance ecosystem for bacterial pathogens and AMR tracking.

How does GenPAx address antimicrobial resistance?

GenPAx tackles antimicrobial resistance by using whole genome sequencing to track bacterial pathogens and their resistance patterns. Its IDEM platform provides high-resolution, automated genomic analysis, enabling healthcare systems and public health agencies to monitor and respond to AMR effectively.

What industries use GenPAx's technology?

GenPAx serves healthcare institutions, public health agencies, food safety and agriculture sectors, and pharmaceutical R&D teams. Its IDEM platform supports infection prevention, disease outbreak monitoring, and AMR surveillance, aligning with One Health initiatives across multiple industries.

What is the IDEM platform by GenPAx?

The IDEM platform by GenPAx is a whole genome sequencing tool designed for high-resolution, automated analysis of bacterial pathogens. It integrates data from healthcare systems, governments, and industries, offering comparable genomic insights for global AMR surveillance and pathogen tracking.

What challenges does GenPAx face?

GenPAx faces challenges such as limited public financial disclosures, reliance on early-stage adoption of whole genome sequencing in healthcare, and competition from established diagnostic companies expanding into genomic surveillance. These factors may impact its market traction and growth.

How is GenPAx engaging with the scientific community?

GenPAx actively engages with the scientific community through industry conferences like ASM Microbe 2024. These appearances highlight its focus on pathogen genomics and AMR surveillance, showcasing its IDEM platform and fostering collaboration with experts in genomics and public health.

Sources

  1. genpax.co — Company overview and product information
  2. www.genpax.co.uk — Recent conference appearance
  3. www.genpax.co.uk — Team composition and company background
  4. www.genpax.co.uk — Healthcare sector application